<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924988</url>
  </required_header>
  <id_info>
    <org_study_id>G120110</org_study_id>
    <nct_id>NCT01924988</nct_id>
  </id_info>
  <brief_title>Prostate Embolization for Benign Prostatic Hyperplasia</brief_title>
  <official_title>Prostate Embolization for Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James B. Spies, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II investigator sponsored FDA-approved Investigational Device Exemption
      protocol, with the primary goal of determining the safety of prostatic artery embolization
      (PAE) for benign prostatic hyperplasia. Our primary goal is to document the frequency of side
      effects, particularly bladder and rectal complications, which may occur as a result of this
      procedure. Secondarily, the study will provide preliminary data to determine its
      effectiveness in diminishing obstructive symptoms associated with BPH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives of the investigation

      This study has a primary goal of determining the safety of prostatic artery embolization
      (PAE) for benign prostatic hyperplasia. Our primary outcome is the frequency of adverse
      events, particularly bladder and rectal complications, which may occur as a result of this
      procedure. Secondarily, the study will allow us to begin to determine its effectiveness in
      diminishing obstructive symptoms associated with BPH.

      Duration of investigation

      The investigation will enroll 30 patients, with a target enrollment period of less than 12
      months. Each patient will be consented for follow-up up to 5 years, but each patient will
      reach the first important safety endpoint 1 week after treatment and the first clinical
      efficacy assessment 3 months after treatment.

      Objectives

      To determine the safety and effectiveness of prostate artery embolization for the treatment
      of BPH.

      Description of study type

      This is a prospective non-comparative treatment study of an initial cohort of 30 patients.

      Study Population

      The patients will be recruited from the urology practice at Georgetown University and from
      other urologists in the area and by patient self-referral. The study also will be announced
      on a study website, the content of which will be approved by the IRB at Georgetown University
      Medical Center.

      The primary outcome is the absence of complications to the bladder, rectum or other pelvic
      structures detected in the first week after therapy. Each patient will be judged free of
      these adverse events or not. For those with an adverse event, the complication will be scored
      using the Society of Interventional Radiology (SIR) definitions. Descriptive statistics will
      be used to summarize these events, along with patient demographics and initial clinical
      status.

      Appropriate parametric and non-parametric tests will be used to assess change in laboratory
      measures, urine flowmetry parameters, and scores from the IPSS and IIEF. Changes in prostate
      volumes and the estimated volume of devascularized tissue will be calculated for each patient
      and outcomes from the different embolics will be compared. Appropriate paired parametric and
      non-parametric tests will be used to determine statistical significance. A p value of 0.05
      will be considered statistically significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Bladder or Rectal Injury</measure>
    <time_frame>Evaluated 1 week after procedure</time_frame>
    <description>Bladder injury as detected by cystoscopy. Rectal injury detected by anoscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of Bladder Injury</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>Bladder injury as detected by cystoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of a Bladder Injury</measure>
    <time_frame>6 months after treatment</time_frame>
    <description>Bladder injury detected by cystoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of a Bladder Injury by Cystoscopy</measure>
    <time_frame>12 months after the procedure</time_frame>
    <description>Number of patients with a bladder injury detected by cystoscopic examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>1week, 3 months, 6months, 12months</time_frame>
    <description>Measure Description: Validated patient reported questionnaire to assess the severity of lower urinary tract symptoms associated with benign prostatic enlargement. Severity of symptom scores range from 0 to 35, with a score of 0-7 considered mild, 8-19 moderate and 20 to 35 severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF)- 5</measure>
    <time_frame>1week, 3 months, 6months, 12months</time_frame>
    <description>Measure Description: IIEF-5 is a 5 question validated patient reported outcome measure or erectile dysfunction (ED), with a range of scores from 5 to 25, and ED was classified into five categories or erectile function based on the scores: severe (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), and no ED (22-25).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QMax (Peak Urinary Flow)</measure>
    <time_frame>1week, 3 months, 6months, 12months</time_frame>
    <description>Measure Description: measure of the peak urinary flow rate as measured by urine flowmetry. Result is in ml/sec.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Prostatic Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic occlusion of the prostate arteries</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prostatic Embolization with Embosphere Micropsheres</intervention_name>
    <description>Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudendal or obturator branches as well.
The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (EmbosphereÂ® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries.</description>
    <arm_group_label>Prostatic Embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. You must have symptoms from BPH for at least 6 months

          2. Your symptoms must meet the entrance criteria, as determined by a short questionnaire
             you will be asked to complete.

          3. You must have urinary flow rates that meet entrance criteria, as measured by a simple
             urination test.

          4. Enlargement of the prostate, as measured by the urologist, with a volume of between 50
             and 100 cc.

          5. You must be at least 50 years of age, but not more than 90.

        Exclusion Criteria:

          -  1. Prostate Cancer 2. Blockage of major arteries in your pelvis or other arterial
             abnormalities that prevent embolization or that might increase risks of injury. You
             will be screened for these conditions if you consent to participate.

             3. Significantly decreased kidney function 4. Prior prostate surgery, whether it has
             been performed via a scope through the penis or with conventional surgery.

             5. Bladder or urinary conditions other than BPH requiring therapy. You will be
             screened for these conditions if you consent to participate.

             6. History of cardiac rhythm abnormalities, congestive heart failure, uncontrolled
             diabetes, significant respiratory disease, or known immunosuppression.

             7. History of clotting disorders. 8. Current medications (use of alpha-blockers within
             two months, 5-alpha-reductase inhibitors within six months, anti-cholinergics within
             two months, and beta blockers, antihistamines, anticonvulsants, or antispasmodics
             within one week of treatment unless you have been on the same drug with a stable
             urination pattern.

             9. Active urinary tract infection 10. Allergy to iodinated contrast agents, collagen
             or gelatin products 11. Acute urinary retention that has NOT been treated by a urinary
             catheter. 12. Significant retained urine after voiding as measured by ultrasound. In
             this case, significant means more than 250 ml (about 1 cup).

             13. Bladder stones or blood in urine within three months 14. Previous rectal surgery,
             excluding hemorrhoidectomy (removal of hemorrhoid), or history of rectal disease 15.
             Prior pelvic irradiation or radical pelvic surgery 16. If you are interested in future
             fertility 17. Unable to speak and read English.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 14, 2013</study_first_submitted>
  <study_first_submitted_qc>August 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2013</study_first_posted>
  <results_first_submitted>May 16, 2019</results_first_submitted>
  <results_first_submitted_qc>November 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2019</results_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>James B. Spies, MD</investigator_full_name>
    <investigator_title>Chair, Department of Radiology</investigator_title>
  </responsible_party>
  <keyword>BPH, benign prostatic hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 20, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT01924988/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prostatic Embolization</title>
          <description>This single-center, Phase I prospective, observational, non-comparative study of the safety and effectiveness of prostate artery embolization for symptomatic benign prostatic hyperplasia. The primary outcome was to determine the frequency of adverse events, focusing on procedure-related bladder and rectal complications as detected by cystoscopic and anoscopic assessment post-treatment. The secondary objectives were to measure the effectiveness in diminishing symptoms of lower urinary tract symptom (LUTS) from treatment.
The inclusion criteria were as follows: Men presenting with benign prostatic hyperplasia with symptoms for at least 6 months. Additional criteria included moderate to severe obstructive urinary tract symptoms as defined as an International Prostate Symptom Score (IPSS) score of 12 or greater, and peak urinary flow (QMax) of less than 12 mL/s or acute urinary retention.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Safety of Prostate Artery Embolization</title>
          <description>This is a study focused on the safety of prostate artery embolization based primarily on cystoscopic evaluation after embolization.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.6" lower_limit="59" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Size</title>
          <units>Grams</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.9" lower_limit="51" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Prostate Symptom Score (IPSS) score</title>
          <description>Validated patient reported questionnaire to assess the severity of lower urinary tract symptoms associated with benign prostatic enlargement. Scores range from 0 to 35, with a score of 0-7 considered mild, 8-19 moderate and 20 to 35 severe symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.2" lower_limit="12" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International index of erectile function- 5 (IIEF-5) score</title>
          <description>International index of erectile function- 5 is a sexual health of men (SHIM) validated 5 question questionnaire assessing erectile function and sexual function, with a range of scores from 5 to 25, higher scores indicating better erectile function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.2" lower_limit="5" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Cystoscopy findings</title>
          <description>Those with normal cystoscopic findings prior to intervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum urinary flow</title>
          <units>ml/sec</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" lower_limit="2.6" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Bladder or Rectal Injury</title>
        <description>Bladder injury as detected by cystoscopy. Rectal injury detected by anoscopy.</description>
        <time_frame>Evaluated 1 week after procedure</time_frame>
        <population>1 patient failed to complete this follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization</title>
            <description>Therapeutic embolization of the prostate arteries to treat benign prostatic hyperplasia.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bladder or Rectal Injury</title>
          <description>Bladder injury as detected by cystoscopy. Rectal injury detected by anoscopy.</description>
          <population>1 patient failed to complete this follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Detection of Bladder Injury</title>
        <description>Bladder injury as detected by cystoscopy</description>
        <time_frame>3 months after treatment</time_frame>
        <population>9 participants failed to complete this follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization</title>
            <description>Therapeutic embolization of the prostate for treatment of benign prostate hyperplasia</description>
          </group>
        </group_list>
        <measure>
          <title>Detection of Bladder Injury</title>
          <description>Bladder injury as detected by cystoscopy</description>
          <population>9 participants failed to complete this follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Detection of a Bladder Injury</title>
        <description>Bladder injury detected by cystoscopy</description>
        <time_frame>6 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Number With Bladder Injury at 3 Months</title>
            <description>Those with bladder injury detected by cystoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Detection of a Bladder Injury</title>
          <description>Bladder injury detected by cystoscopy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Patients evaluated</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number with bladder injury</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Detection of a Bladder Injury by Cystoscopy</title>
        <description>Number of patients with a bladder injury detected by cystoscopic examination</description>
        <time_frame>12 months after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cystoscopy Outcomes 12 Months</title>
            <description>Number of patients with a bladder injury 12 months after treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Detection of a Bladder Injury by Cystoscopy</title>
          <description>Number of patients with a bladder injury detected by cystoscopic examination</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number evaluated</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number with bladder injury</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Prostate Symptom Score (IPSS)</title>
        <description>Measure Description: Validated patient reported questionnaire to assess the severity of lower urinary tract symptoms associated with benign prostatic enlargement. Severity of symptom scores range from 0 to 35, with a score of 0-7 considered mild, 8-19 moderate and 20 to 35 severe symptoms.</description>
        <time_frame>1week, 3 months, 6months, 12months</time_frame>
        <population>Some participants did not complete follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization</title>
            <description>Therapeutic embolization of the prostate arteries to treat benign prostatic hyperplasia.</description>
          </group>
        </group_list>
        <measure>
          <title>International Prostate Symptom Score (IPSS)</title>
          <description>Measure Description: Validated patient reported questionnaire to assess the severity of lower urinary tract symptoms associated with benign prostatic enlargement. Severity of symptom scores range from 0 to 35, with a score of 0-7 considered mild, 8-19 moderate and 20 to 35 severe symptoms.</description>
          <population>Some participants did not complete follow-up</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="3" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="2" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="3" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="17" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Function (IIEF)- 5</title>
        <description>Measure Description: IIEF-5 is a 5 question validated patient reported outcome measure or erectile dysfunction (ED), with a range of scores from 5 to 25, and ED was classified into five categories or erectile function based on the scores: severe (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), and no ED (22-25).</description>
        <time_frame>1week, 3 months, 6months, 12months</time_frame>
        <population>Some participants did not complete follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization</title>
            <description>Therapeutic embolization of the prostate arteries to treat benign prostatic hyperplasia.</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Function (IIEF)- 5</title>
          <description>Measure Description: IIEF-5 is a 5 question validated patient reported outcome measure or erectile dysfunction (ED), with a range of scores from 5 to 25, and ED was classified into five categories or erectile function based on the scores: severe (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), and no ED (22-25).</description>
          <population>Some participants did not complete follow-up</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="9" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="5" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="5" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="7" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QMax (Peak Urinary Flow)</title>
        <description>Measure Description: measure of the peak urinary flow rate as measured by urine flowmetry. Result is in ml/sec.</description>
        <time_frame>1week, 3 months, 6months, 12months</time_frame>
        <population>Some participants did not complete follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Artery Embolization</title>
            <description>Therapeutic embolization of the prostate arteries to treat benign prostatic hyperplasia.</description>
          </group>
        </group_list>
        <measure>
          <title>QMax (Peak Urinary Flow)</title>
          <description>Measure Description: measure of the peak urinary flow rate as measured by urine flowmetry. Result is in ml/sec.</description>
          <population>Some participants did not complete follow-up</population>
          <units>milliliters per second</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="0" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="6.8" upper_limit="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="2" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="2.2" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Society of Interventional Radiology Adverse Events Classification Class A Minor, no treatment Class B Minor, medical or nominal therapy Class C Major, re-admission for less than 48 hrs, ED visit, minor intervention Class D Major, re-admission for greater than 48 hrs, major intervention Class E Major, permanent patient injury Class F Major, patient death</desc>
      <group_list>
        <group group_id="E1">
          <title>Adverse Events</title>
          <description>Summary of adverse events</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache and confusion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Headache and confusion reported but not documented by research staff</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria or urethral pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>Self limited blood in urine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>acute prostatitis</sub_title>
                <description>Prostate tenderness, dysuria, and positive urinary culture</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Reported fever and chills</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Fever and chills reported but without infection, not documented by research staff</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There as poor compliance by patients to the follow-up protocol beyond 1 week post procedure. Only 10 of 15 patients participated in follow-up at three months. By 12 months, only 3 patients provided some elements of follow-up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James B. Spies MD MPH</name_or_title>
      <organization>Georgetown University Medical Center</organization>
      <phone>202-444-3450</phone>
      <email>spiesj@gunet.georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

